Clinical trial
GM-CSF, Sargramostim in Women With Recurrent Ovarian Cancer
NCT00157573 · Massachusetts General Hospital, Other · Completed
Key facts
| NCT number | NCT00157573 |
|---|---|
| Title | GM-CSF, Sargramostim in Women With Recurrent Ovarian Cancer |
| Official title | Phase II Trial of GM-CSF in Women With Asymptomatic Ovarian, Primary Peritoneal, or Tubal Carcinoma |
| Lead sponsor | Massachusetts General Hospital, Other |
| Collaborators | Dana-Farber Cancer Institute Bayer Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer, Fallopian Tube Cancer |
| Intervention type | Drug |
| Interventions | GM-CSF, sargramostim |
| Enrollment | 72 |
| Start date | Dec 1, 2004 |
| Primary completion | Oct 1, 2008 |
| Completion | Apr 1, 2010 |
| First posted | Sep 12, 2005 |
| Last update posted | May 8, 2017 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: